Nektar Therapeutics (NKTR) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $67.10 -1.84%
Revenue Growth %: -11.4%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -11.4%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of $5.33, $0.11 better than the analyst estimate of $5.22. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.03 billion.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
